News After a long biotech IPO lull, LB Pharma chances its arm After a promising start, IPOs all but fizzled out this year, but LB Pharma is hoping that won't stymy its chances of completing a Nasdaq listing.
News Stada revives talk of an IPO – if conditions improve Germany's Stada has said it may make another attempt to seek a public listing in the autumn, after delaying its plans earlier this year.
R&D Built for one: The case for custom formulation in the era of... The precision medicine market is projected to exceed $175 billion by 2030, reflecting continued growth and interest in innovative approaches that tailor therapeutics that accounts for diffe
News Caris swells its planned IPO, seeking $5.7bn valuation AI-powered techbio firm Caris Life Sciences has raised the target price for its IPO, pointing to strong demand among investors.
News Digital health firm Omada prices $150m IPO In another sign of recovery in digital health investing, Omada Health has priced an IPO that could value the company at more than $1.1 billion.
News Digital player Hinge Health rises sharply after NYSE debut In a signal of a return to investor appetite for digital health stocks, Hinge Health has raised an impressive $437 million in an IPO.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.